{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:50:52Z","timestamp":1782215452575,"version":"3.54.5"},"reference-count":67,"publisher":"Termedia Sp. z.o.o.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol J Pathol"],"abstract":"<jats:p>Medullary thyroid carcinomas (MTCs) are 75% sporadic and 25% hereditary. This study aimed to determine the\u00a0histopathological parameters and molecular changes of\u00a0sporadic MTCs in a\u00a0university hospital by targeted next-generation sequencing (NGS) including 62 genes. All RET mutations were missense mutations. &lt;br \/&gt;\nEIF1AX was suggested by artificial intelligence as a gene of interest for further analysis; subsequent testing revealed a pathogenic missense mutation in this gene in a patient with advanced-stage disease, who died at the 25th month of follow-up due to liver metastasis. We identified different gene mutations that could be associated with nodal metastasis in the\u00a0presence or absence of\u00a0RET mutation. We identified mutations that may be involved in tumour progression and have prognostic significance, such as HRAS, MAP3K1, and EIF1AX. &lt;br \/&gt;\nWe observed KDR mutation in this cohort. Although driver mutations in sporadic medullary thyroid carcinoma (sMTC) mostly come from targeted NGS data in tumours from patients with localised disease, NGS findings can also be used for therapeutic purposes in advanced-stage sMTC cases with progressive local-regional or distant metastatic disease. &lt;br \/&gt;\nWe believe that additional studies should be conducted with a\u00a0larger number of\u00a0patients so that the\u00a0findings can be included in the\u00a0treatment guidelines to be prepared.<\/jats:p>","DOI":"10.5114\/pjp.2025.156557","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:24:18Z","timestamp":1764321858000},"page":"195-213","source":"Crossref","is-referenced-by-count":1,"title":["Molecular profiling of\u00a0sporadic medullary thyroid carcinomas \u2013 a\u00a0next-generation sequencing-based study"],"prefix":"10.5114","volume":"76","author":[{"given":"Serdar","family":"Altinay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altan","family":"Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Emre","family":"G\u00fclba\u011fc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Cem","family":"Dural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eaban","family":"Tekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba Kul","family":"K\u00f6pr\u00fcl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisa Beg\u00fcm","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Mert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dclkan","family":"\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"ref-1687716","unstructured":"Lloyd RV, Douglas BR, Young WF. Endocrine diseases. Ameri\u00adcan Registry of\u00a0Pathology and the\u00a0Armed Forces Institute of\u00a0Pathology, Washington 2002."},{"key":"ref-1687717","unstructured":"Livolsi VA. Surgical pathology of\u00a0the\u00a0thyroid. Saunders, Philadelphia 1990."},{"key":"ref-1687718","doi-asserted-by":"crossref","unstructured":"Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the\u00a0management of\u00a0medullary thyroid carcinoma. Thyroid 2015; 25: 567-610.","DOI":"10.1089\/thy.2014.0335"},{"key":"ref-1687719","doi-asserted-by":"crossref","unstructured":"Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of\u00a0thyroid cancer. Nat Rev Endocrinol 2011; 7: 569-580.","DOI":"10.1038\/nrendo.2011.142"},{"key":"ref-1687720","doi-asserted-by":"crossref","unstructured":"Chernock RD, Hagemann IS. Molecular pathology of\u00a0hereditary and sporadic medullary thyroid carcinomas. Am J Clin Pathol 2015; 143: 768-777.","DOI":"10.1309\/AJCPHWACTTUYJ7DD"},{"key":"ref-1687721","doi-asserted-by":"crossref","unstructured":"Barletta JA, Nos\u00e9 V, Sadow PM. Genomics and epigenomics of\u00a0medullary thyroid carcinoma: from sporadic disease to familial manifestations. Endocr Pathol 2021; 32: 35-43.","DOI":"10.1007\/s12022-021-09664-3"},{"key":"ref-1687722","doi-asserted-by":"crossref","unstructured":"Margraf RL, Crockett DK, Krautscheid PMF, Seamons R, Calderon FRO, Wittwer CT, et al. Multiple endocrine neoplasia type 2 RET protooncogene database: repository of\u00a0MEN2-associated RET sequence variation and reference for genotype\/phenotype correlations. Hum Mutat 2009; 30: 548-556.","DOI":"10.1002\/humu.20928"},{"key":"ref-1687723","doi-asserted-by":"crossref","unstructured":"Jin LX, Moley JF. Surgery for lymph node metastases of\u00a0medullary thyroid carcinoma: a\u00a0review. Cancer 2016; 122:  358-366.","DOI":"10.1002\/cncr.29761"},{"key":"ref-1687724","doi-asserted-by":"crossref","unstructured":"Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, et al. Somatic mutations in the\u00a0RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 2008; 284: 21-27.","DOI":"10.1016\/j.mce.2007.12.016"},{"key":"ref-1687725","doi-asserted-by":"crossref","unstructured":"Romei C, Ugolini C, Cosci B, Torregrossa L, Vivaldi A, Ciampi R, et al. Low prevalence of\u00a0the\u00a0somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid 2012; 22: 476-481.","DOI":"10.1089\/thy.2011.0358"},{"key":"ref-1687726","doi-asserted-by":"crossref","unstructured":"Aydo\u011fan B\u0130, Y\u00fcksel B, Tuna MM, Navdar Ba\u015faran M, Akkurt Kocaeli A, Ert\u00f6rer ME, et al. Distribution of\u00a0RET mutations and evaluation of\u00a0treatment approaches in hereditary medullary thyroid carcinoma in Turkey. J Clin Res Pediatr Endocrinol 2016; 8: 13-20.","DOI":"10.4274\/jcrpe.2219"},{"key":"ref-1687727","doi-asserted-by":"crossref","unstructured":"Erdogan MF, G\u00fcrsoy A, Ozgen G, Cakir M, Bayram F, Ersoy R, et al. Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study. J Endocrinol Invest 2005; 28: 806-809.","DOI":"10.1007\/BF03347570"},{"key":"ref-1687728","doi-asserted-by":"crossref","unstructured":"Tiedje V, Ting S, Walter RF, Herold T, Worm K, Badziong J,  et al. Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients. Eur J Endocrinol 2016; 175: 173-180.","DOI":"10.1530\/EJE-16-0252"},{"key":"ref-1687729","doi-asserted-by":"crossref","unstructured":"Wei S, LiVolsi VA, Montone KT, Morrissette JJD, Baloch ZW. Detection of\u00a0molecular alterations in medullary thyroid carcinoma using next-generation sequencing: an \u0131nstitutional experience. Endocr Pathol 2016; 27: 359- 362.","DOI":"10.1007\/s12022-016-9446-3"},{"key":"ref-1687730","doi-asserted-by":"crossref","unstructured":"Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, et al. Early malignant progression of\u00a0hereditary medullary thyroid cancer. N Engl J Med 2003; 349: 1517-1525.","DOI":"10.1056\/NEJMoa012915"},{"key":"ref-1687731","doi-asserted-by":"crossref","unstructured":"Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of\u00a0mutations in thyroid cancer. J Clin Endocrinol  Metab 2013; 98: E1852-1860.","DOI":"10.1210\/jc.2013-2292"},{"key":"ref-1687732","doi-asserted-by":"crossref","unstructured":"Simbolo M, Mian C, Barollo S, Fassan M, Mafficini A, Neves D, et al. High-throughput mutation profiling improves diagnostic stratification of\u00a0sporadic medullary thyroid carcinomas. Virchows Arch 2014; 465: 73-78.","DOI":"10.1007\/s00428-014-1589-3"},{"key":"ref-1687733","doi-asserted-by":"crossref","unstructured":"Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, et al. Exomic sequencing of\u00a0medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013; 98: E364-369.","DOI":"10.1210\/jc.2012-2703"},{"key":"ref-1687734","doi-asserted-by":"crossref","unstructured":"Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, et al. Comprehensive genomic profiling of\u00a0clinically advanced medullary thyroid carcinoma. Oncology 2016; 90: 339-346.","DOI":"10.1159\/000445978"},{"key":"ref-1687735","doi-asserted-by":"crossref","unstructured":"Diwaker C, Sarathi V, Jaiswal SK, Shah R, Deshmukh A, Thomas AE, et al. Hereditary medullary thyroid carcinoma syndromes: experience from western India. Fam Cancer 2021; 20: 241-251.","DOI":"10.1007\/s10689-020-00219-9"},{"key":"ref-1687736","doi-asserted-by":"crossref","unstructured":"Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26: 1135-1145.","DOI":"10.1038\/nbt1486"},{"key":"ref-1687737","doi-asserted-by":"crossref","unstructured":"Schuster SC. Next-generation sequencing transforms today\u2019s biology. Nat Methods 2008; 5: 16-18.","DOI":"10.1038\/nmeth1156"},{"key":"ref-1687738","doi-asserted-by":"crossref","unstructured":"Yang A, Zhang W, Wang J, Yang K, Han Y, Zhang L. Review on the\u00a0application of\u00a0machine learning algorithms in the\u00a0sequence data mining of\u00a0DNA. Front Bioeng Biotechnol 2020; 8: 1032.","DOI":"10.3389\/fbioe.2020.01032"},{"key":"ref-1687739","doi-asserted-by":"crossref","unstructured":"Giani AM, Gallo GR, Gianfranceschi L, Formenti G. Long walk to genomics: history and current approaches to genome sequencing and assembly. Comput Struct Biotechnol J 2020; 18: 9-19.","DOI":"10.1016\/j.csbj.2019.11.002"},{"key":"ref-1687740","doi-asserted-by":"crossref","unstructured":"Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of\u00a0RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 2011; 96: E863-868.","DOI":"10.1210\/jc.2010-1921"},{"key":"ref-1687741","doi-asserted-by":"crossref","unstructured":"Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, et al. Somatic RAS mutations occur in a\u00a0large proportion of\u00a0sporadic RET-negative medullary thyroid carcinomas and extend to a\u00a0previously unidentified exon. J Clin Endocrinol Metab 2012; 97: E2031-2035.","DOI":"10.1210\/jc.2012-2092"},{"key":"ref-1687742","unstructured":"Endocrine and Neuroendocrine Tumors, WHO Classification of\u00a0Tumors, 5th Edition, Volume 10, Lyon (France). WHO Classification of\u00a0Tumours Editorial Board 2025."},{"key":"ref-1687743","doi-asserted-by":"crossref","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The\u00a0eighth edition AJCC cancer staging manual: continuing to build a\u00a0bridge from a\u00a0population-based to a\u00a0more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin 2017; 67: 93-99.","DOI":"10.3322\/caac.21388"},{"key":"ref-1687744","unstructured":"Organisation mondiale de la sant\u00e9, Centre international de recherche sur le cancer, eds. WHO classification of\u00a0tumours of\u00a0endocrine organs. 4th ed. International Agency for Research on Cancer, Lyon 2017."},{"key":"ref-1687745","doi-asserted-by":"crossref","unstructured":"Xu B, Fuchs TL, Ahmadi S, Alghamdi M, Alzumaili B,  Bani MA, et al. International medullary thyroid carcinoma grading system: a\u00a0validated grading system for medullary thyroid carcinoma. J Clin Oncol 2022; 40: 96-104.","DOI":"10.1200\/JCO.21.01329"},{"key":"ref-1687746","doi-asserted-by":"crossref","unstructured":"Koperek O, Scheuba C, Puri C, Birner P, Haslinger C, Rettig W, et al. Molecular characterization of\u00a0the\u00a0desmoplastic tumor stroma in medullary thyroid carcinoma. Int J Oncol 2007; 31: 59-67.","DOI":"10.3892\/ijo.31.1.59"},{"key":"ref-1687747","unstructured":"Albores-Saavedra J, Rose GG, Ibanez ML, Russell WO, Grey CE, Dmochowski L. The\u00a0amylo\u0131d \u0131n sol\u0131d carc\u0131noma of\u00a0the\u00a0thyro\u0131d gland. Sta\u0131n\u0131ng character\u0131st\u0131cs, t\u0131ssue culture, and electron m\u0131croscop\u0131c observat\u0131ons. Lab Invest 1964; 13: 77-93."},{"key":"ref-1687748","doi-asserted-by":"crossref","unstructured":"Perry A, Molberg K, Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of\u00a0the\u00a0thyroid: separation of\u00a0distinct histologic and biologic entities. Cancer 1996; 77: 750-756.","DOI":"10.1002\/(SICI)1097-0142(19960215)77:4<750::AID-CNCR22>3.0.CO;2-Z"},{"key":"ref-1687749","unstructured":"Available from: https:\/\/documents.cap.org\/protocols\/Thyroid_4.4.0.0.REL_CAPCP.pdf."},{"key":"ref-1687750","unstructured":"Available from: https:\/\/www.genome.jp\/kegg\/pathway.html."},{"key":"ref-1687751","unstructured":"Available from: https:\/\/karchinlab.github.io\/CHASMplus."},{"key":"ref-1687752","doi-asserted-by":"crossref","unstructured":"Tokheim C, Karchin R. CHASMplus reveals the\u00a0scope of\u00a0somatic missense mutations driving human cancers. Cell Syst 2019; 9: 9-23.e8.","DOI":"10.1016\/j.cels.2019.05.005"},{"key":"ref-1687753","doi-asserted-by":"crossref","unstructured":"Polistena A, Sanguinetti A, Lucchini R, Galasse S, Monacelli M, Avenia S, et al. Timing and extension of\u00a0lymphadenectomy in medullary thyroid carcinoma: a\u00a0case series from a\u00a0single institution. Int J Surg 2017; 41: S70-S74.","DOI":"10.1016\/j.ijsu.2017.04.026"},{"key":"ref-1687754","doi-asserted-by":"crossref","unstructured":"Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS, Hickey RC, et al. Medullary carcinoma of\u00a0the\u00a0thyroid. A\u00a0study of\u00a0the\u00a0clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984; 63: 319-342.","DOI":"10.1097\/00005792-198411000-00001"},{"key":"ref-1687755","doi-asserted-by":"crossref","unstructured":"Gharib H, McConahey WM, Tiegs RD, Bergstralh EJ, Goellner JR, Grant CS, et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of\u00a065 patients treated during 1946 through 1970. Mayo Clin Proc 1992; 67: 934-940.","DOI":"10.1016\/S0025-6196(12)60923-9"},{"key":"ref-1687756","doi-asserted-by":"crossref","unstructured":"Schr\u00f6der S, B\u00f6cker W, Baisch H, B\u00fcrk CG, Arps H, Meiners I, et al. Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content. Cancer 1988; 61: 806-816.","DOI":"10.1002\/1097-0142(19880215)61:4<806::AID-CNCR2820610428>3.0.CO;2-G"},{"key":"ref-1687757","doi-asserted-by":"crossref","unstructured":"Al-Qurayshi Z, Khadra H, Chang K, Pagedar N, Randolph GW, Kandil E. Risk and survival of\u00a0patients with medullary thyroid cancer: national perspective. Oral Oncol 2018; 83:  59-63.","DOI":"10.1016\/j.oraloncology.2018.06.002"},{"key":"ref-1687758","doi-asserted-by":"crossref","unstructured":"Moses LE, Oliver JR, Rotsides JM, Shao Q, Patel KN, Morris LGT, et al. Nodal disease burden and outcome of\u00a0medullary thyroid carcinoma. Head Neck 2021; 43: 577-584.","DOI":"10.1002\/hed.26511"},{"key":"ref-1687759","doi-asserted-by":"crossref","unstructured":"Hyer SL, Vini L, A\u2019Hern R, Harmer C. Medullary thyroid cancer: multivariate analysis of\u00a0prognostic factors influencing survival. Eur J Surg Oncol 2000; 26: 686-690.","DOI":"10.1053\/ejso.2000.0981"},{"key":"ref-1687760","doi-asserted-by":"crossref","unstructured":"Miccoli P, Minuto MN, Ugolini C, Molinaro E, Basolo F, Berti P,  et al. Clinically unpredictable prognostic factors in the\u00a0outcome of\u00a0medullary thyroid cancer. Endocr Relat Cancer 2007; 14: 1099-1105.","DOI":"10.1677\/ERC-07-0128"},{"key":"ref-1687761","doi-asserted-by":"crossref","unstructured":"Contarino A, Dolci A, Maggioni M, Porta FM, Lopez G, Verga U, et al. Is encapsulated medullary thyroid carcinoma associated with a\u00a0better prognosis? A\u00a0case series and a\u00a0review of\u00a0the\u00a0literature. Front Endocrinol (Lausanne) 2022; 13: 866572.","DOI":"10.3389\/fendo.2022.866572"},{"key":"ref-1687762","doi-asserted-by":"crossref","unstructured":"Cupisti K, Wolf A, Raffel A, Schott M, Miersch D, Yang Q,  et al. Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a\u00a0single institution\u2019s experience over 20 years. Ann Surg 2007; 246: 815-821.","DOI":"10.1097\/SLA.0b013e31813e66b9"},{"key":"ref-1687763","doi-asserted-by":"crossref","unstructured":"Guy\u00e9tant S, Josselin N, Savagner F, Rohmer V, Michalak S, Saint-Andr\u00e9 JP. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients. Mod Pathol 2003; 16: 756-763.","DOI":"10.1097\/01.MP.0000081727.75778.0C"},{"key":"ref-1687764","doi-asserted-by":"crossref","unstructured":"Kaserer K, Scheuba C, Neuhold N, Weinh\u00e4usel A, Haas OA, Vierhapper H, et al. Sporadic versus familial medullary thyroid microcarcinoma: a\u00a0histopathologic study of\u00a050 consecutive patients. Am J Surg Pathol 2001; 25: 1245-1251.","DOI":"10.1097\/00000478-200110000-00004"},{"key":"ref-1687765","doi-asserted-by":"crossref","unstructured":"Salvatore D, Santoro M, Schlumberger M. The\u00a0importance of\u00a0the\u00a0RET gene in thyroid cancer and therapeutic implications. Nat Rev Endocrinol 2021; 17: 296-306.","DOI":"10.1038\/s41574-021-00470-9"},{"key":"ref-1687766","doi-asserted-by":"crossref","unstructured":"De Groot JWB, Links TP, Plukker JTM, Lips CJM, Hofstra RMW. RET as a\u00a0diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006; 27: 535-560.","DOI":"10.1210\/er.2006-0017"},{"key":"ref-1687767","doi-asserted-by":"crossref","unstructured":"Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The\u00a0landscape of\u00a0kinase fusions in cancer. Nat Commun 2014; 5: 4846.","DOI":"10.1038\/ncomms5846"},{"key":"ref-1687768","doi-asserted-by":"crossref","unstructured":"Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET aberrations in diverse cancers: next-generation sequencing of\u00a04,871 patients. Clin Cancer Res 2017; 23: 1988-1997.","DOI":"10.1158\/1078-0432.CCR-16-1679"},{"key":"ref-1687769","doi-asserted-by":"crossref","unstructured":"Hutchison CA. DNA sequencing: bench to bedside and beyond. Nucleic Acids Res 2007; 35: 6227-6237.","DOI":"10.1093\/nar\/gkm688"},{"key":"ref-1687770","doi-asserted-by":"crossref","unstructured":"Erdogdu IH., Orenay-Boyacioglu S, Boyacioglu O, Kahraman-Cetin N, Guler H, Turan M, et al. Microsatellite instability and somatic gene variant profile in solid organ tumors. Arch Med Sci 2024; 20: 1672-1679.","DOI":"10.5114\/aoms\/185326"},{"key":"ref-1687771","doi-asserted-by":"crossref","unstructured":"Adamska M, Kowal-Wi\u0153niewska E, Czerwi\u00f1ska-Rybak J, Kiwerska K, Bara\u00f1ska M, Gronowska W, et al. Defining the\u00a0mutatio- nal profile of\u00a0lower-risk myelodysplastic neoplasm patients with respect to disease progression using next-generation sequencing and pyrosequencing. Contemp Oncol 2023; 27: 269-279.","DOI":"10.5114\/wo.2023.135365"},{"key":"ref-1687772","doi-asserted-by":"crossref","unstructured":"Qu N, Shi X, Zhao JJ, Guan H, Zhang TT, Wen SS, et al. Genomic and transcriptomic characterization of\u00a0sporadic medullary thyroid carcinoma. Thyroid 2020; 30: 1025-1036.","DOI":"10.1089\/thy.2019.0531"},{"key":"ref-1687773","unstructured":"Altaykan A, Ersoy-Evans S, Emre S, Orhan D, G\u00fc\u00e7er S, Erkin G. Multiple endocrine neoplasia type 2b associated with lichen nitidus. Eur J Dermatol 2007; 17: 292-294."},{"key":"ref-1687774","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Antona C, Pallares J, Montero-Conde C, Inglada-P\u00e9rez L, Castelblanco E, Landa I, et al. Overexpression and activation of\u00a0EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 2010; 17: 7-16.","DOI":"10.1677\/ERC-08-0304"},{"key":"ref-1687775","doi-asserted-by":"crossref","unstructured":"Verrienti A, Tallini G, Colato C, Boichard A, Checquolo S, Pecce V, et al. RET mutation and increased angiogenesis in medullary thyroid carcinomas. Endocr Relat Cancer 2016; 23: 665-676.","DOI":"10.1530\/ERC-16-0132"},{"key":"ref-1687776","doi-asserted-by":"crossref","unstructured":"Kann BH, Hosny A, Aerts HJWL. Artificial intelligence for clinical oncology. Cancer Cell 2021; 39: 916-927.","DOI":"10.1016\/j.ccell.2021.04.002"},{"key":"ref-1687777","doi-asserted-by":"crossref","unstructured":"Maliszewska A, Leandro-Garcia LJ, Castelblanco E, Maci\u00e0 A, de Cubas A, Gom\u00e9z-L\u00f3pez G, et al. Differential gene expression of\u00a0medullary thyroid carcinoma reveals specific markers associated with genetic conditions. Am J Pathol 2013; 182: 350-362.","DOI":"10.1016\/j.ajpath.2012.10.025"},{"key":"ref-1687778","doi-asserted-by":"crossref","unstructured":"Karunamurthy A, Panebianco F, J Hsiao S, Vorhauer J, Nikiforova MN, Chiosea S, et al. Prevalence and phenotypic correlations of\u00a0EIF1AX mutations in thyroid nodules. Endocr Relat Cancer 2016; 23: 295-301.","DOI":"10.1530\/ERC-16-0043"},{"key":"ref-1687779","doi-asserted-by":"crossref","unstructured":"Sim\u00f5es-Pereira J, Moura MM, Marques IJ, Rito M, Cabrera RA, Leite V, et al. The\u00a0role of\u00a0EIF1AX in thyroid cancer tumourigenesis and progression. J Endocrinol Invest 2019; 42: 313-318.","DOI":"10.1007\/s40618-018-0919-8"},{"key":"ref-1687780","doi-asserted-by":"crossref","unstructured":"Karslioglu French E, Nikitski AV, Yip L, Nikiforova MN, Nikiforov YE, Carty SE. Clinicopathological features and outcomes of\u00a0thyroid nodules with EIF1AX mutations. Endocr Relat Cancer 2022; 29: 467-473.","DOI":"10.1530\/ERC-22-0041"},{"key":"ref-1687781","doi-asserted-by":"crossref","unstructured":"Hinnebusch AG. Molecular mechanism of\u00a0scanning and start codon selection in eukaryotes. Microbiol Mol Biol Rev 2011; 75: 434-467.","DOI":"10.1128\/MMBR.00008-11"},{"key":"ref-1687782","unstructured":"Wang Q, Holst J. L-type amino acid transport and cancer: targeting the\u00a0mTORC1 pathway to inhibit neoplasia. Am  J Cancer Res 2015; 5: 1281-1294."}],"container-title":["Polish Journal of Pathology"],"original-title":[],"link":[{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-209629-136504","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-209629-136504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:13:32Z","timestamp":1782213212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.polishjournalofpathology.com\/Molecular-profiling-of-sporadic-medullary-thyroid-carcinomas-a-next-generation-sequencing,209629,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"alternative-id":["209629"],"URL":"https:\/\/doi.org\/10.5114\/pjp.2025.156557","relation":{},"ISSN":["1233-9687","2084-9869"],"issn-type":[{"value":"1233-9687","type":"print"},{"value":"2084-9869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}